[1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-imino-1-methylpurin-9-yl)oxolan-2-yl]-2-methylbutan-2-yl]oxy-(2-hydroxybutan-2-yl)phosphinic acid

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: [1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-imino-1-methylpurin-9-yl)oxolan-2-yl]-2-methylbutan-2-yl]oxy-(2-hydroxybutan-2-yl)phosphinic acid
• 化学式: C₁₉H₃₂N₅O₇P
• 分子量: 473.5
• InChiKey: WXRMXDNGZSXPHK-XJROGMIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  174
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20140249208A1

  公开（公告）日：2014-09-04

  The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
• US20140255467A1
  申请人：——

  公开号：US20140255467A1

  公开（公告）日：2014-09-11
• METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20150051268A1

  公开（公告）日：2015-02-19

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules for their use in improving organ viability and/or longevity.
• HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20160022840A1

  公开（公告）日：2016-01-28

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
• US9061059B2
  申请人：——

  公开号：US9061059B2

  公开（公告）日：2015-06-23